» Articles » PMID: 26807687

Withdrawal of Life-Sustaining Therapy in Patients With Intracranial Hemorrhage: Self-Fulfilling Prophecy or Accurate Prediction of Outcome?

Overview
Journal Crit Care Med
Date 2016 Jan 26
PMID 26807687
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Withdrawal of life-sustaining therapy may lead to premature limitations of life-saving treatments among patients with intracranial hemorrhage, representing a self-fulfilling prophecy. We aimed to determine whether our algorithm for the withdrawal of life-sustaining therapy decision would accurately identify patients with a high probability of poor outcome, despite aggressive treatment.

Design: Retrospective analysis of prospectively collected data.

Setting: Tertiary-care Neuro-ICU.

Patients: Intraparenchymal, subdural, and subarachnoid hemorrhage patients.

Interventions: Baseline demographics, clinical status, and hospital course were assessed to determine the predictors of in-hospital mortality and 12-month death/severe disability among patients receiving maximal therapy. Multivariable logistic regression models developed on maximal therapy patients were applied to patients who underwent withdrawal of life-sustaining therapy to predict their probable outcome had they continued maximal treatment. A validation cohort of propensity score-matched patients was identified from the maximal therapy cohort, and their predicted and actual outcomes compared.

Measurements And Main Results: Of 383 patients enrolled, there were 128 subarachnoid hemorrhage (33.4%), 134 subdural hematoma (35.0%), and 121 intraparenchymal hemorrhage (31.6%). Twenty-six patients (6.8%) underwent withdrawal of life-sustaining therapy and died, 41 (10.7%) continued maximal therapy and died in hospital, and 316 (82.5%) continued maximal therapy and survived to discharge. The median predicted probability of in-hospital death among withdrawal of life-sustaining therapy patients was 35% had they continued maximal therapy, whereas the median predicted probability of 12-month death/severe disability was 98%. In the propensity-matched validation cohort, 16 of 20 patients had greater than or equal to 80% predicted probability of death/severe disability at 12 months, matching the observed outcomes and supporting the strength and validity of our prediction models.

Conclusions: The withdrawal of life-sustaining therapy decision may contribute to premature in-hospital death in some patients who may otherwise have been expected to survive to discharge. However, based on probability models, nearly all of the patients who underwent withdrawal of life-sustaining therapy would have died or remained severely disabled at 12 months had maximal therapy been continued. Withdrawal of life-sustaining therapy may not represent a self-fulfilling prophecy.

Citing Articles

Intracranial multimodal monitoring in neurocritical care (Neurocore-iMMM): an open, decentralized consensus.

Barrit S, Al Barajraji M, El Hadwe S, Niset A, Foreman B, Park S Crit Care. 2024; 28(1):427.

PMID: 39707556 PMC: 11660549. DOI: 10.1186/s13054-024-05211-8.


Multimodal assessment improves neuroprognosis performance in clinically unresponsive critical-care patients with brain injury.

Rohaut B, Calligaris C, Hermann B, Perez P, Faugeras F, Raimondo F Nat Med. 2024; 30(8):2349-2355.

PMID: 38816609 PMC: 11333287. DOI: 10.1038/s41591-024-03019-1.


The Role of Nursing Care in the Management of Patients with Traumatic Subarachnoid Hemorrhage.

Miao Q, Yan Y, Zhou M, Sun X Galen Med J. 2024; 12:e3013.

PMID: 38774855 PMC: 11108670. DOI: 10.31661/gmj.v12i0.3013.


Recovery Potential in Patients Who Died After Withdrawal of Life-Sustaining Treatment: A TRACK-TBI Propensity Score Analysis.

Sanders W, Barber J, Temkin N, Foreman B, Giacino J, Williamson T J Neurotrauma. 2024; 41(19-20):2336-2348.

PMID: 38739032 PMC: 11564834. DOI: 10.1089/neu.2024.0014.


Association of Neighborhood Socioeconomic Status With Withdrawal of Life-Sustaining Therapies After Intracerebral Hemorrhage.

Melmed K, Lewis A, Kuohn L, Marmo J, Rossan-Raghunath N, Torres J Neurology. 2024; 102(3):e208039.

PMID: 38237088 PMC: 11097759. DOI: 10.1212/WNL.0000000000208039.